Loading…
Serina Therapeutics, Inc. is projected to rise to $2.39 by 2027, a +16% move from its current price of $2.06. SER is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.99 | $2.06 | $2.14 | +0.07% |
| Aug 6 | $1.96 | $2.06 | $2.17 | +0.14% |
| Aug 7 | $1.94 | $2.06 | $2.20 | +0.21% |
| Aug 8 | $1.92 | $2.07 | $2.22 | +0.29% |
| Aug 9 | $1.90 | $2.07 | $2.24 | +0.36% |
| Aug 10 | $1.89 | $2.07 | $2.26 | +0.43% |
| Aug 11 | $1.88 | $2.07 | $2.28 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.88 | $2.07 | $2.28 | +0.50% |
| Week 2 | $1.81 | $2.08 | $2.39 | +1.00% |
| Week 3 | $1.77 | $2.09 | $2.47 | +1.51% |
| Week 4 | $1.73 | $2.10 | $2.55 | +2.02% |
| Week 5 | $1.70 | $2.11 | $2.62 | +2.53% |
| Week 6 | $1.67 | $2.12 | $2.69 | +3.04% |
| Week 7 | $1.65 | $2.13 | $2.76 | +3.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252.
Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
The asset is Serina Therapeutics, Inc. (SER). The current price is $2.13 and the market capitalization is $31.94M, with a market rank of 4572.
Technically, the 30-day snapshot shows bullish sentiment, with RSI(14) at 60. The 50-day SMA sits at $1.87 and the 200-day SMA at $2.70. Near-term support is at $1.74 and resistance at $2.20. The 30-day range spans from $1.57 to $2.90.
Forecast-wise, the 2026 avg price is $2.13 with a min of $1.28 and a max of $3.22 (ROI 0), indicating neutral near-term taste. Longer horizon forecasts show growing upside, with 2040 avg $4.77 and 2050 avg $7.59, corresponding to ROI of 124.1% and 256.2% respectively, and bullish sentiment in later years.
A major floor 26.7% below — a decisive break under it would weaken the trend.
The nearest floor, 12.1% below — buyers have tended to step in here.
The nearest ceiling, 6.8% above — a clean break opens room to run.
A major ceiling 47.1% above — clearing it would confirm fresh momentum.
Key SER support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SER market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.06 | Buy | $2.05 | Buy |
| MA 10 | $2.09 | Sell | $2.06 | Sell |
| MA 20 | $2.08 | Sell | $2.05 | Buy |
| MA 50 | $1.96 | Buy | $1.99 | Buy |
| MA 100 | $1.94 | Buy | $2.10 | Sell |
| MA 200 | $2.54 | Sell | $2.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.21 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -87.01 | Neutral |
| Williams %R (14) | -78.26 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 2.56 | Buy |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 21.74 | Neutral |
| TRIX (15) | 0.35 | Buy |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 28.40 | Buy |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 2.03 | Buy |
| ADX (14) | 7.52 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bullish, with RSI at 60 and momentum supported by price action around key levels. The stock trades above the 50-day moving average ($1.87) but below the 200-day moving average ($2.70), suggesting a cautiously positive short-term bias. Support sits at $1.74 and resistance at $2.20, providing defined cliffs for downside and upside moves.
In the current 30-day range, the price has traded between $1.57 and $2.90, indicating a relatively wide but actionable window for near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.28 | $2.06 | $2.86 | 0% | Neutral | |
| $1.85 | $2.39 | $3.30 | +16% | Neutral | |
| $1.73 | $2.33 | $3.38 | +13% | Neutral | |
| $1.60 | $2.23 | $3.35 | +8% | Neutral | |
| $1.45 | $2.07 | $3.21 | +1% | Neutral | |
| $1.54 | $2.26 | $3.61 | +10% | Neutral | |
| $1.77 | $2.67 | $4.35 | +29% | Bullish | |
| $1.92 | $2.96 | $4.95 | +44% | Bullish | |
| $1.90 | $3.00 | $5.11 | +46% | Bullish | |
| $1.79 | $2.88 | $5.00 | +40% | Bullish | |
| $2.29 | $4.08 | $7.62 | +98% | Bullish | |
| $2.80 | $6.00 | $12.49 | +191% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.28 | $2.06 | $2.52 | +0.00% |
| September 2026 | $1.83 | $2.18 | $2.69 | +5.97% |
| October 2026 | $1.82 | $2.20 | $2.75 | +0.70% |
| November 2026 | $1.77 | $2.16 | $2.73 | -1.97% |
| December 2026 | $1.83 | $2.24 | $2.86 | +3.88% |
Click any year to see its month-by-month SER forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SER is projected to trade between $1.28 and $2.86, averaging $2.06 — a potential gain of 0% from today's $2.06. A consolidation phase looks the most probable path here.
Serina Therapeutics, Inc.'s 2027 outlook centres on $2.39, within a $1.85 to $3.30 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2028, SER could reach as high as $3.38, with a base case around $2.33 and support toward $1.73 — roughly +13% from $2.06. A consolidation phase looks the most probable path here.
Expect SER to range from $1.60 to $3.35 through 2029. The $2.23 average target implies a +8% move from current prices. That is -5% versus the projected 2028 average. Price action looks broadly range-bound.
The SER price prediction for 2030 points to an average of $2.07 (low $1.45, high $3.21) — a potential gain of +1% on today's $2.06. A consolidation phase looks the most probable path here.
In 2031, SER is projected to trade between $1.54 and $3.61, averaging $2.26 — a potential gain of +10% from today's $2.06. That is up +9% on the projected 2030 average. Price action looks broadly range-bound.
Serina Therapeutics, Inc.'s 2032 outlook centres on $2.67, within a $1.77 to $4.35 range. That is up +18% on the projected 2031 average. That marks a +29% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SER could reach as high as $4.95, with a base case around $2.96 and support toward $1.92 — roughly +44% from $2.06. Momentum favours further upside here.
Expect SER to range from $1.90 to $5.11 through 2034. The $3.00 average target implies a +46% move from current prices. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SER price prediction for 2035 points to an average of $2.88 (low $1.79, high $5.00) — a potential gain of +40% on today's $2.06. Momentum favours further upside here.
In 2040, SER is projected to trade between $2.29 and $7.62, averaging $4.08 — a potential gain of +98% from today's $2.06. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Serina Therapeutics, Inc.'s 2050 outlook centres on $6.00, within a $2.80 to $12.49 range. That is up +47% on the projected 2040 average. That marks a +191% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SER today (≈ 485.436893 SER) could be worth
$2,912.5
+$1,912.5 (+191%) by 2050 · US Dollar
Based on the average projected SER price of $6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SERwould be worth at today's price.
$1,000 invested in SER on Jul 31, 2025 (≈ 180.505416 SER) would be worth
$371.84
-$628.16 (-62.8%) today · 0.37× · US Dollar
Based on a SER entry price of $5.54 vs. today's $2.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.07 | $995.17 | -0.5% |
| 1 month ago | $1.92 | $1,072.92 | +7.3% |
| 3 months ago | $1.82 | $1,133.74 | +13.4% |
| 6 months ago | $2.72 | $757.35 | -24.3% |
| 1 year ago | $5.54 | $371.84 | -62.8% |
| All time (5.0y) ago | $48.21 | $42.73 | -95.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SER forecast.
Our base-case forecast reaches $4.10 around 2050.
Implied market cap at $4.10: $61.49M
The multi-year forecast paints meaningful upside after 2026. The 2030 projection shows a min of $1.34, an average of $2.05 and a max of $3.42, with a negative ROI of -3.6% and a neutral sentiment, highlighting near-term uncertainty. From 2032 onward, the outlook turns bullish, with the 2032 average at $3.18 and a max of $5.62 (ROI 49.5%), and a 2033 average of $3.26 (ROI 53.1%), followed by steady gains through 2034–2035 (avg $3.37 and $3.30; max up to $6.25).
The 2040 forecast is notably stronger, with an average of $4.77 and a max of $9.86 (ROI 124.1%), signaling robust longer-term upside. By 2050, the average reaches $7.59 with a max of $17.45 (ROI 256.2%), and a bullish sentiment persists. These figures reflect estimates, not guarantees, and actual results may differ due to market and development outcomes.
Tap a question to reveal the answer.
2030 min $1.34, avg $2.05, max $3.42; ROI -3.6%; sentiment NEUTRAL.
Forecasts show neutral near-term ( 2026), followed by bullish momentum from 2032 onward, with 2040 avg $4.77 (ROI 124.1%) and 2050 avg $7.59 (ROI 256.2%), but these are estimates, not guarantees.
2040 max is $9.86, so $10 by 2040 is not projected; by 2050 the max is $17.45.
2050 min $3.41, avg $7.59, max $17.45; ROI 256.2%; sentiment BULLISH.
Current price is $2.13 and market cap is $31.94M; rank 4572.
Serina Therapeutics, Inc. Community Discussion
0Share your Serina Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.